CAC
IMUX icon

Cowen and Company’s Immunic IMUX Stock Holding History

Cowen and Company’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-31,706
Closed -$476K – 694
2023
Q4 		$476K Hold
31,706
– – 0.03% 180
2023
Q3 		$466K Sell
31,706
-4,080
-11% -$78.4K 0.03% 177
2023
Q2 		$898K Hold
35,786
– – 0.07% 153
2023
Q1 		$533K Sell
35,786
-43,316
-55% -$804K 0.06% 113
2022
Q4 		$1.11M Sell
79,102
-40,967
-34% -$1.12M 0.12% 89
2022
Q3 		$3.79M Hold
120,069
– – 0.36% 42
2022
Q2 		$4.17M Sell
120,069
-5,646
-4% -$362K 0.4% 48
2022
Q1 		$14.2M Buy
125,715
+100,129
+391% +$11.6M 1.37% 21
2021
Q4 		$2.45M Buy
+25,586
New +$2.3M 0.22% 93

Other funds holding IMUX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Cowen and Company's IMUX Position: Q1 2024 in Review

Cowen and Company sold out of Immunic (IMUX) in Q1 2024, closing a stake of 31,706 shares — an estimated $476K sold.

Cowen and Company first reported a position in IMUX in Q4 2021 and held it in 9 quarters. The position peaked at $14.2M in Q1 2022. 59 funds tracked by Wall St. Rank hold IMUX as of Q1 2024.

  • Cowen and Company reported no remaining Immunic position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 31,706 Immunic shares in Q1 2024, an estimated $476K.
  • Cowen and Company first reported a position in Immunic in Q4 2021 and held it in 9 quarters.
  • Cowen and Company's Immunic position peaked at $14.2M in Q1 2022.
  • 59 funds tracked by Wall St. Rank held Immunic as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.